Natera (NTRA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Natera (NASDAQ:NTRA) is expected to release its Q2 2025 earnings report on August 7, projecting a loss of ($0.60) per share and revenue of $476.84 million.
• The company reported ($0.50) earnings per share in the prior quarter, exceeding estimates, with revenue growth of 36.5% compared to the same quarter last year.
• Analysts from Evercore ISI and Piper Sandler have recently upgraded Natera, with target prices set at $170.00 and $210.00, respectively, indicating a generally positive outlook for the stock.

Natera (NASDAQ:NTRA - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $476.84 million for the quarter. Natera has set its FY 2025 guidance at EPS.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same period in the prior year, the business posted ($0.56) earnings per share. The firm's revenue for the quarter was up 36.5% compared to the same quarter last year. On average, analysts expect Natera to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Natera Stock Performance

Shares of Natera stock traded down $7.30 during trading hours on Thursday, hitting $133.66. The company's stock had a trading volume of 1,511,087 shares, compared to its average volume of 1,495,497. Natera has a twelve month low of $92.14 and a twelve month high of $183.00. The firm has a fifty day moving average of $158.12 and a 200-day moving average of $156.45. The stock has a market cap of $18.25 billion, a price-to-earnings ratio of -90.92 and a beta of 1.73.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 6,111 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $157.10, for a total transaction of $960,038.10. Following the transaction, the chief executive officer owned 179,071 shares of the company's stock, valued at $28,132,054.10. This trade represents a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 3,045 shares of the firm's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total value of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares in the company, valued at approximately $8,990,082. This represents a 4.45% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,936 shares of company stock worth $7,483,846. 7.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC boosted its position in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock worth $221,000 after purchasing an additional 96 shares during the period. Focus Partners Wealth lifted its holdings in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock worth $847,000 after buying an additional 474 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock worth $644,000 after buying an additional 1,847 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of research analyst reports. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research report on Monday. Piper Sandler upped their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Barclays upped their price objective on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. UBS Group upped their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Finally, Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Natera has a consensus rating of "Moderate Buy" and an average target price of $183.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.